JP2009082138A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2009082138A5 JP2009082138A5 JP2008301520A JP2008301520A JP2009082138A5 JP 2009082138 A5 JP2009082138 A5 JP 2009082138A5 JP 2008301520 A JP2008301520 A JP 2008301520A JP 2008301520 A JP2008301520 A JP 2008301520A JP 2009082138 A5 JP2009082138 A5 JP 2009082138A5
- Authority
- JP
- Japan
- Prior art keywords
- temperature
- medium
- hmba
- cell line
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Claims (15)
- 組換えポリペプチドを産生する方法であって
哺乳動物細胞株を培地中で35℃〜38℃の温度で培養してから、29℃〜36℃の第ニの温度にシフトさせ;
培養培地にヘキサメチレン・ビスアセトアミド(HMBA)を添加する
ことを含んでなり;
ここにおいて、哺乳動物細胞株が、組換えポリペプチドを産生するように遺伝子操作されており、そして
第一の温度から第二の温度へのシフトの後、数時間ないし数日後に、HMBAが添加される、
前記方法。 - 酪酸の塩を、第一の温度から第二の温度へのシフトから、数時間ないし数日後に添加す、請求項1の方法。
- 培地中の酪酸の塩の濃度が、0.1mM〜2mMである、請求項2の方法
- 培地中のHMBAの濃度が、0.1ミリモル〜20ミリモルである、請求項1ないし3のいずれか1項の方法。
- 培地中のHMBAの濃度が、0.5ミリモル〜10ミリモルである、請求項4の方法。
- 培地中のHMBAの濃度が、0.1ミリモル〜5ミリモルである、請求項4の方法。
- 培地中に、キサンチン愉導体を、第一の温度から第二の温度へのシフトから、数時間ないし数日後に添加する、請求項1ないし6のいずれか1項の方法。
- キサンチン誘導体がカフェインであり、そして、カフェインが0.01ないし3.0mMの濃度で添加される、請求項7の方法。
- 培地が血清不含である、請求項1ないし8のいずれか1項の方法。
- 細胞株が、CHO細胞株あるいはハイブリドーマ細胞株である、請求項1ないし9のいずれか1項の方法。
- 組換えポリペプチドが、RANK:Fc、II型インターロイキン−1受容体、TNFR:Fc、CD40リガンド、TRAIL、flt3リガンド、IL−4受容体、G−CSF、エリスロポエチン、および抗体からなる群より選択される、請求項1ないし10のいずれか1項の方法。
- さらに、培地から組換えポリペプチドを回収することを含む、請求項1ないし11のいずれか1項の方法。
- ポリペプチドを産生する方法であって
ポリペプチドを発現可能な哺乳動物細胞株を35℃ないし38℃の温度で培養し、そして、次いで
血清不含の培地中、少なくとも5日間、29℃ないし36℃の温度で細胞を培養する、
ことを含んでなり、
ここにおいて、HMBA及び酪酸の塩を、0.5ないし10mM HMBA及び0.1ないし2mM 酪酸塩の濃度で、温度シフトの後、数時間ないし数日後に添加する、
前記方法。 - ポリペプチドが、RANK:Fc、II型インターロイキン−1受容体、TNFR:Fc、CD40リガンド、TRAIL、flt3リガンド、IL−4受容体、G−CSF、エリスロポエチン、および抗体からなる群より選択される、請求項13の方法。
- ポリペプチドを産生するように遺伝子操作されているCHO細胞株、及びHMBAを含んでなる血清不含の産生培地、を含んでなる細胞培養物であって、
ここにおいて、培養物は、35℃ないし38℃の第一の温度で培養されており、そして、次いで、29℃ないし36℃の第二の温度にシフトして少なくとも5日間培養されている、並びに、
、第一の温度から第二の温度へのシフトの後、数時間ないし数日後にHMBAが添加される、
前記細胞培養物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36824802P | 2002-03-27 | 2002-03-27 | |
US36824602P | 2002-03-27 | 2002-03-27 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003580502A Division JP2005521401A (ja) | 2002-03-27 | 2003-03-27 | ポリペプチド産生を増加させる方法 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2009082138A JP2009082138A (ja) | 2009-04-23 |
JP2009082138A5 true JP2009082138A5 (ja) | 2009-06-04 |
JP4414472B2 JP4414472B2 (ja) | 2010-02-10 |
Family
ID=28678222
Family Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003580502A Pending JP2005521401A (ja) | 2002-03-27 | 2003-03-27 | ポリペプチド産生を増加させる方法 |
JP2008024395A Expired - Lifetime JP4414466B2 (ja) | 2002-03-27 | 2008-02-04 | ポリペプチド産生を増加させる方法 |
JP2008301520A Expired - Lifetime JP4414472B2 (ja) | 2002-03-27 | 2008-11-26 | ポリペプチド産生を増加させる方法 |
Family Applications Before (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2003580502A Pending JP2005521401A (ja) | 2002-03-27 | 2003-03-27 | ポリペプチド産生を増加させる方法 |
JP2008024395A Expired - Lifetime JP4414466B2 (ja) | 2002-03-27 | 2008-02-04 | ポリペプチド産生を増加させる方法 |
Country Status (9)
Country | Link |
---|---|
US (2) | US6872549B2 (ja) |
EP (1) | EP1497444B1 (ja) |
JP (3) | JP2005521401A (ja) |
AU (1) | AU2003220529B2 (ja) |
CA (1) | CA2480121C (ja) |
ES (1) | ES2557741T3 (ja) |
MX (1) | MXPA04009381A (ja) |
PL (1) | PL376821A1 (ja) |
WO (1) | WO2003083066A2 (ja) |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050005310A1 (en) * | 1999-07-12 | 2005-01-06 | Genentech, Inc. | Expression vectors and methods |
WO2003083066A2 (en) * | 2002-03-27 | 2003-10-09 | Immunex Corporation | Methods for increasing polypeptide production |
WO2004046340A2 (en) * | 2002-11-14 | 2004-06-03 | Genentech, Inc. | Intron fusion construct and method of using for selecting high-expressing production cell lines |
JP2007525176A (ja) * | 2003-04-25 | 2007-09-06 | イミュネックス・コーポレーション | 組換えタンパク質発現の誘導剤 |
EP1656148A4 (en) * | 2003-08-21 | 2011-07-20 | Duchesnay Inc | SUPPLEMENT OF MICRONUTRIENT |
JP4520987B2 (ja) * | 2003-08-21 | 2010-08-11 | デュシェネ インク | チャイルドプルーフ微量栄養素サプリメント |
WO2005063813A2 (en) * | 2003-12-23 | 2005-07-14 | Applied Research Systems Ars Holding N.V. | Process for the production of tumor necrosis factor-binding proteins |
BRPI0611901A2 (pt) | 2005-06-14 | 2012-08-28 | Amgen, Inc | composição, liofilizado, kit, e, processo para preparar uma composição |
WO2007049567A1 (ja) * | 2005-10-24 | 2007-05-03 | Kyowa Hakko Kogyo Co., Ltd. | 物質の製造方法 |
SI1969007T1 (sl) | 2005-12-20 | 2014-03-31 | Bristol-Myers Squibb Company | Sestavki in postopki za izdelavo sestavka |
AR058568A1 (es) | 2005-12-20 | 2008-02-13 | Bristol Myers Squibb Co | Metodos para producir una composicion con moleculas ctla4-ig a partir de un medio de cultivo |
EP2623609B1 (en) * | 2006-02-10 | 2017-01-04 | Life Technologies Corporation | Labeling and detection of post translationally modified proteins |
CA2661175C (en) * | 2006-08-14 | 2014-08-05 | Biocontrol Systems, Inc. | Method for detecting pathogens depending on incubation temperature variation |
US8911964B2 (en) | 2006-09-13 | 2014-12-16 | Abbvie Inc. | Fed-batch method of making human anti-TNF-alpha antibody |
CA2910619A1 (en) | 2006-09-13 | 2008-03-20 | Abbvie Inc. | Cell culture improvements |
AU2008232732A1 (en) * | 2007-03-28 | 2008-10-09 | Medarex, Inc. | Methods of gene amplification and expression |
TW200902708A (en) * | 2007-04-23 | 2009-01-16 | Wyeth Corp | Methods of protein production using anti-senescence compounds |
US20090023186A1 (en) * | 2007-07-22 | 2009-01-22 | Excellgene Sa | Use of valproic acid for enhancing production of recombinant proteins in mammalian cells |
WO2009114693A1 (en) * | 2008-03-12 | 2009-09-17 | Wyeth | Method for identifying cells suitable for large-scale production of recombinant proteins |
KR20140015152A (ko) * | 2009-12-02 | 2014-02-06 | 악셀레론 파마 인코포레이티드 | Fc 융합 단백질의 혈청 반감기를 증가시키는 조성물들 및 방법들 |
CN103080221B (zh) | 2010-09-30 | 2015-11-25 | 大金工业株式会社 | 防熔滴剂以及树脂组合物 |
WO2012091124A1 (ja) * | 2010-12-28 | 2012-07-05 | 中外製薬株式会社 | 動物細胞の培養方法 |
US9062106B2 (en) | 2011-04-27 | 2015-06-23 | Abbvie Inc. | Methods for controlling the galactosylation profile of recombinantly-expressed proteins |
WO2012170938A1 (en) | 2011-06-08 | 2012-12-13 | Acceleron Pharma Inc. | Compositions and methods for increasing serum half-life |
IL310968A (en) | 2011-07-01 | 2024-04-01 | Amgen Inc | Mammalian cell culture |
EP2653548A1 (de) | 2012-04-17 | 2013-10-23 | Greenovation Biotech GmbH | Verfahren zur Erhöhung der Sekretion rekombinanter Proteine |
US9150645B2 (en) | 2012-04-20 | 2015-10-06 | Abbvie, Inc. | Cell culture methods to reduce acidic species |
WO2013158273A1 (en) | 2012-04-20 | 2013-10-24 | Abbvie Inc. | Methods to modulate c-terminal lysine variant distribution |
US9067990B2 (en) | 2013-03-14 | 2015-06-30 | Abbvie, Inc. | Protein purification using displacement chromatography |
WO2013176754A1 (en) | 2012-05-24 | 2013-11-28 | Abbvie Inc. | Novel purification of antibodies using hydrophobic interaction chromatography |
AU2013309506A1 (en) | 2012-09-02 | 2015-03-12 | Abbvie Inc. | Methods to control protein heterogeneity |
US9512214B2 (en) | 2012-09-02 | 2016-12-06 | Abbvie, Inc. | Methods to control protein heterogeneity |
SG11201507230PA (en) | 2013-03-12 | 2015-10-29 | Abbvie Inc | Human antibodies that bind human tnf-alpha and methods of preparing the same |
US9017687B1 (en) | 2013-10-18 | 2015-04-28 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same using displacement chromatography |
WO2014151878A2 (en) | 2013-03-14 | 2014-09-25 | Abbvie Inc. | Methods for modulating protein glycosylation profiles of recombinant protein therapeutics using monosaccharides and oligosacharides |
WO2014159579A1 (en) | 2013-03-14 | 2014-10-02 | Abbvie Inc. | MUTATED ANTI-TNFα ANTIBODIES AND METHODS OF THEIR USE |
EP2970888A4 (en) * | 2013-03-15 | 2017-04-12 | Theocorp Holding Co., LLC | Theobromine compositions useful for increasing fetal weight gain and enhancing bone properties |
EP3052640A2 (en) | 2013-10-04 | 2016-08-10 | AbbVie Inc. | Use of metal ions for modulation of protein glycosylation profiles of recombinant proteins |
US9085618B2 (en) | 2013-10-18 | 2015-07-21 | Abbvie, Inc. | Low acidic species compositions and methods for producing and using the same |
US8946395B1 (en) | 2013-10-18 | 2015-02-03 | Abbvie Inc. | Purification of proteins using hydrophobic interaction chromatography |
US9181337B2 (en) | 2013-10-18 | 2015-11-10 | Abbvie, Inc. | Modulated lysine variant species compositions and methods for producing and using the same |
US20150139988A1 (en) | 2013-11-15 | 2015-05-21 | Abbvie, Inc. | Glycoengineered binding protein compositions |
CN114917185B (zh) | 2016-10-21 | 2023-11-14 | 美国安进公司 | 药物配制品及其制备方法 |
KR102190790B1 (ko) * | 2018-10-19 | 2020-12-15 | 주식회사 프로젠 | 변형된 egf 단백질의 생산 방법 |
US11339197B2 (en) | 2017-10-23 | 2022-05-24 | Progen Co., Ltd. | Modified EGF protein, production method therefor, and use thereof |
WO2022140389A1 (en) | 2020-12-22 | 2022-06-30 | Amgen Inc. | Cell culture method |
Family Cites Families (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3824286A (en) | 1970-07-07 | 1974-07-16 | Lever Brothers Ltd | Preparation of polyacetylalkylene diamines |
EP0005476B1 (de) | 1978-05-17 | 1981-12-30 | Dr. Karl Thomae GmbH | Verfahren zur Herstellung von Humaninterferon |
US4301249A (en) * | 1980-07-23 | 1981-11-17 | Merck & Co., Inc. | High titer production of hepatitis A virus |
US4357422A (en) | 1980-08-14 | 1982-11-02 | Massachusetts Institute Of Technology | Method of enhancing interferon production |
US4416986A (en) | 1981-01-16 | 1983-11-22 | Merck & Co., Inc. | Methods of producing HBsAg |
US4473647A (en) | 1981-02-27 | 1984-09-25 | Amf Inc. | Tissue culture medium |
US6936694B1 (en) | 1982-05-06 | 2005-08-30 | Intermune, Inc. | Manufacture and expression of large structural genes |
AU588819B2 (en) | 1984-10-29 | 1989-09-28 | Immunex Corporation | Cloning of human granulocyte-macrophage colony stimulating factor gene |
US4992472A (en) | 1987-06-16 | 1991-02-12 | The United States Of America As Represented By The Department Of Health And Human Services | Chemical differentiating agents |
US4965195A (en) | 1987-10-26 | 1990-10-23 | Immunex Corp. | Interleukin-7 |
US4968607A (en) | 1987-11-25 | 1990-11-06 | Immunex Corporation | Interleukin-1 receptors |
US5075222A (en) | 1988-05-27 | 1991-12-24 | Synergen, Inc. | Interleukin-1 inhibitors |
WO1990005183A1 (en) | 1988-10-31 | 1990-05-17 | Immunex Corporation | Interleukin-4 receptors |
US5055608A (en) | 1988-11-14 | 1991-10-08 | Sloan-Kettering Institute For Cancer Research | Novel potent inducers of thermal differentiation and method of use thereof |
US5330744A (en) | 1988-11-14 | 1994-07-19 | Sloan-Kettering Institute For Cancer Research | Method for increasing sensitivity to chemically induced terminal differentiation |
ZA899421B (en) | 1988-12-14 | 1990-09-26 | Merrell Dow Pharma | Method of potentiating natural killer cell activity |
IL94611A (en) | 1989-06-05 | 1994-12-29 | Organogenesis Inc | Medium for cell cultures containing insulin or growth factor similar to insulin, transferrin or iron ion, triiodothyronine or thyroxine and method of use |
US5395760A (en) | 1989-09-05 | 1995-03-07 | Immunex Corporation | DNA encoding tumor necrosis factor-α and -β receptors |
DE59010908D1 (de) | 1989-09-12 | 2000-08-10 | Hoffmann La Roche | TNF-bindende Proteine |
US6204363B1 (en) | 1989-10-16 | 2001-03-20 | Amgen Inc. | Stem cell factor |
US5272064A (en) | 1989-12-19 | 1993-12-21 | Amgen Inc. | DNA molecules encoding platelet-derived growth factor B chain analogs and method for expression thereof |
US5149792A (en) | 1989-12-19 | 1992-09-22 | Amgen Inc. | Platelet-derived growth factor B chain analogs |
US5272071A (en) | 1989-12-22 | 1993-12-21 | Applied Research Systems Ars Holding N.V. | Method for the modification of the expression characteristics of an endogenous gene of a given cell line |
US5350683A (en) | 1990-06-05 | 1994-09-27 | Immunex Corporation | DNA encoding type II interleukin-1 receptors |
AU651596B2 (en) | 1990-06-05 | 1994-07-28 | Immunex Corporation | Type II interleukin-1 receptors |
US5369108A (en) | 1991-10-04 | 1994-11-29 | Sloan-Kettering Institute For Cancer Research | Potent inducers of terminal differentiation and methods of use thereof |
CA2146559A1 (en) | 1992-10-23 | 1994-05-11 | Melanie K. Spriggs | Methods of preparing soluble, oligomeric proteins |
US5420019A (en) * | 1993-02-02 | 1995-05-30 | Xoma Corporation | Stable bactericidal/permeability-increasing protein muteins |
US5554512A (en) | 1993-05-24 | 1996-09-10 | Immunex Corporation | Ligands for flt3 receptors |
US20010010922A1 (en) | 1994-06-09 | 2001-08-02 | Riccardo Dalla-Favera | Cloning and uses of the genetic locus bcl-6 |
US5981713A (en) | 1994-10-13 | 1999-11-09 | Applied Research Systems Ars Holding N.V. | Antibodies to intereleukin-1 antagonists |
US5705364A (en) | 1995-06-06 | 1998-01-06 | Genentech, Inc. | Mammalian cell culture process |
ATE310813T1 (de) | 1995-06-29 | 2005-12-15 | Immunex Corp | Apoptosis induzierendes cytokin |
JP4306813B2 (ja) | 1995-09-19 | 2009-08-05 | アスビオファーマ株式会社 | 動物細胞の新規培養方法 |
US6613544B1 (en) | 1995-12-22 | 2003-09-02 | Amgen Inc. | Osteoprotegerin |
US6096728A (en) | 1996-02-09 | 2000-08-01 | Amgen Inc. | Composition and method for treating inflammatory diseases |
USRE37234E1 (en) | 1996-11-01 | 2001-06-19 | Nitromed, Inc. | Nitrosated and nitrosylated phosphodiestrase inhibitor compounds, compositions and their uses |
US6271349B1 (en) | 1996-12-23 | 2001-08-07 | Immunex Corporation | Receptor activator of NF-κB |
WO1998028010A2 (en) | 1996-12-24 | 1998-07-02 | Hyal Pharmaceutical Corporation | Use of moieties for binding to hyaluronan and icam-1 |
US6235883B1 (en) | 1997-05-05 | 2001-05-22 | Abgenix, Inc. | Human monoclonal antibodies to epidermal growth factor receptor |
WO1999032605A1 (en) | 1997-12-19 | 1999-07-01 | Novo Nordisk A/S | Method for producing heterologous proteins in eukaryotic cells on an industrial scale using nucleotide-manipulating agents |
US6337072B1 (en) | 1998-04-03 | 2002-01-08 | Hyseq, Inc. | Interleukin-1 receptor antagonist and recombinant production thereof |
JP2002526109A (ja) | 1998-10-02 | 2002-08-20 | ザ ガバメント オブ ザ ユナイテッドステイツ オブ アメリカ アズ リプレゼンテッド バイ ザ セクレタリー デパートメント オブ ヘルス アンド ヒューマン サービシーズ ザ ナショナル インステ | アポトーシス誘導物質と方法 |
US6660843B1 (en) | 1998-10-23 | 2003-12-09 | Amgen Inc. | Modified peptides as therapeutic agents |
US6506598B1 (en) | 1999-04-26 | 2003-01-14 | Genentech, Inc. | Cell culture process |
WO2001027299A1 (en) | 1999-10-13 | 2001-04-19 | Immunex Corporation | Vectors and methods for recombinant protein expression |
AU1920301A (en) | 1999-11-17 | 2001-05-30 | Immunex Corporation | Receptor activator of nf-kappa b |
AU2001259432B2 (en) | 2000-05-03 | 2005-04-21 | Amgen Inc. | Modified peptides, comprising an FC domain, as therapeutic agents |
WO2003083066A2 (en) * | 2002-03-27 | 2003-10-09 | Immunex Corporation | Methods for increasing polypeptide production |
-
2003
- 2003-03-27 WO PCT/US2003/009266 patent/WO2003083066A2/en active IP Right Grant
- 2003-03-27 EP EP03716840.8A patent/EP1497444B1/en not_active Expired - Lifetime
- 2003-03-27 US US10/400,334 patent/US6872549B2/en not_active Expired - Lifetime
- 2003-03-27 JP JP2003580502A patent/JP2005521401A/ja active Pending
- 2003-03-27 PL PL376821A patent/PL376821A1/pl unknown
- 2003-03-27 MX MXPA04009381A patent/MXPA04009381A/es active IP Right Grant
- 2003-03-27 CA CA2480121A patent/CA2480121C/en not_active Expired - Fee Related
- 2003-03-27 AU AU2003220529A patent/AU2003220529B2/en not_active Expired
- 2003-03-27 ES ES03716840.8T patent/ES2557741T3/es not_active Expired - Lifetime
-
2005
- 2005-02-04 US US11/051,149 patent/US7452695B2/en not_active Expired - Lifetime
-
2008
- 2008-02-04 JP JP2008024395A patent/JP4414466B2/ja not_active Expired - Lifetime
- 2008-11-26 JP JP2008301520A patent/JP4414472B2/ja not_active Expired - Lifetime
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2009082138A5 (ja) | ||
Ho et al. | Engineering strategies for improving the CO2 fixation and carbohydrate productivity of Scenedesmus obliquus CNW-N used for bioethanol fermentation | |
JP2019004912A5 (ja) | ||
CA2480121A1 (en) | Methods for increasing polypeptide production | |
Crosby et al. | Extreme thermophiles as emerging metabolic engineering platforms | |
BR112012027282A2 (pt) | meio de cultura de células aperfeiçoado | |
Qiao et al. | Engineering cyanobacteria as cell factories for direct trehalose production from CO2 | |
JP2007502114A5 (ja) | ||
JP2015521848A5 (ja) | ||
JP2013545491A5 (ja) | ||
BR112012009828A8 (pt) | método para a produção de uma imunoglobulina glicosilada | |
RU2014128987A (ru) | Быстрый способ клонирования и экспрессии сегментов гена родственной вариабельной области антитела | |
JP6961713B2 (ja) | タガトース生産用組成物及びこれを用いたタガトースの製造方法 | |
RU2010119233A (ru) | Новые гидрогеназы, выделенные из thermococcus spp., гены, кодирующие эти гидрогеназы, и способы продуцирования водорода с использованием микроорганизмов, содержащих указанные гены | |
JP2016513478A5 (ja) | ||
AU2019400151B2 (en) | Recombinant Escherichia coli system, construction method thereof, and usage in synthesis of α-1,2-fucosylated oligosaccharide | |
RU2015144020A (ru) | Среды для культивирования клеток и способы получения антител | |
TW201446966A (zh) | 新穎o-磷絲胺酸輸出蛋白及其製造方法 | |
US20240279699A1 (en) | ENZYME COMPOSITION FOR PREPARING Beta-NICOTINAMIDE MONONUCLEOTIDE, AND APPLICATION THEREOF | |
Pembroke et al. | Metabolic engineering of the model photoautotrophic cyanobacterium synechocystis for ethanol production: Optimization strategies and challenges | |
CN109706104B (zh) | sll0528基因在提高集胞藻PCC6803乙醇耐受性中的应用 | |
KR101903553B1 (ko) | 중쇄 아미노카르복시산의 생산 방법 | |
JP2009100702A5 (ja) | ||
CN104845961A (zh) | 产1,3-二羟基丙酮重组基因工程菌的固定化及应用 | |
KR102157781B1 (ko) | 디카르복시산 생산을 위한 미생물 및 이를 이용한 디카르복시산 생산방법 |